Patents Examined by Marianne DiBrino
  • Patent number: 10485882
    Abstract: This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of TR1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: November 26, 2019
    Assignee: UTI Limited Partnership
    Inventor: Pedro Santamaria
  • Patent number: 10478508
    Abstract: Embodiments herein report compositions of and methods for making and using alpha-1 antitrypsin (AAT) fusion molecules or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating an AAT fusion molecule of use in pharmaceutically acceptable compositions to treat a subject in need of AAT therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking AAT or derivative thereof to an immune fragment.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: November 19, 2019
    Assignees: The Regents of the University of Colorado, A Body Corporate, Konkuk University Industry Cooperation Foundation
    Inventors: Soohyun Kim, Charles A. Dinarello
  • Patent number: 10434136
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: October 8, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski
  • Patent number: 10416158
    Abstract: The present application discloses proteins or peptides and methods of using such proteins or peptides to evaluate the immune status of a patient. In one embodiment, proteins or peptides may be used to detect endogenous calnexin specific CD4 T cells. In one preferred embodiment, the proteins or peptides may comprise peptide-MHCII tetramers (pMHC tetramers).
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 17, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Bruce Steven Klein, Marcel Wuethrich
  • Patent number: 10386367
    Abstract: A method for producing an examination reagent includes adding a helper ligand to an unfolded receptor protein in an initial solution so as to provide a pre-solution of the examination reagent with a folded receptor protein. The folded receptor protein comprises a bonded helper ligand which can be exchanged with an examination peptide.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: August 20, 2019
    Assignee: JACOBS UNIVERSITY BREMEN GGMBH
    Inventors: Sebastian Hartmut Springer, Sunil Kumar Saini
  • Patent number: 10350298
    Abstract: The present invention relates to protein constructs that comprise one or more peptides, proteins, factors, compounds or other components as further described herein that are linked to and/or are linked to each other via a helical polymeric backbone. The constructs of the invention are suitable for administration to a human or animal body and can be used for pharmaceutical purposes, for example, for immunotherapy, such as for treating cancer and for other immunological applications, as well as for other therapeutic, prophylactic and/or diagnostic purposes.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: July 16, 2019
    Assignees: Stichting Katholieke Universiteit, Radboud University Nijmegen Medical Centre, Stichting Katholieke Universiteit, meer in het bijzonder Radboud Universiteit Nijmegen
    Inventors: Alan Edward Rowan, Carl Gustav Figdor
  • Patent number: 10336809
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: July 2, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10336808
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: July 2, 2019
    Assignee: Dako Denmark A/S
    Inventors: Jøgen Schøller, Henrik Pedersen, Liselotte Brix
  • Patent number: 10316075
    Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: June 11, 2019
    Assignees: Oregon Health & Science University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
  • Patent number: 10239916
    Abstract: The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: March 26, 2019
    Assignees: Board of Regents, The University of Texas Systems, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Constantin G. Ioannides, Martin L. Campbell, Catherine A. O'Brian, George E. Peoples
  • Patent number: 10174114
    Abstract: The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: January 8, 2019
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang
  • Patent number: 10159725
    Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gastric cancers (GC).
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: December 25, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10139395
    Abstract: Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 molecule and an HLA-DPB1*0501 molecule; a composition for use in the method; a therapeutic and/or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and/or prophylactic method; and others.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: November 27, 2018
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventor: Haruo Sugiyama
  • Patent number: 10124045
    Abstract: This disclosure provides methods of making functionalized PEG iron oxide nanoparticles.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: November 13, 2018
    Assignee: UTI LIMITED PARTNERSHIP
    Inventor: Pedro Santamaria
  • Patent number: 10125351
    Abstract: An industrial preparation of natural killer cells (NKs) is produced by: using umbilical cord blood and peripheral blood from legitimate sources as raw materials, obtaining stem cells by a method for extracting and separating karyocytes, or using FICOLL® or PERCOLL® density gradient media centrifugation to isolate and screen out karyocytes; diluting the above-mentioned karyocytes with cell culture medium, adding interferon, interleukin, CD3 antibody, and human albumin, loading them together into a bioreactor for perfusion culture, and then performing multiplication culture; the passage number of natural killer cells from multiplication culture is no less than 8, and the culture time is no less than 4 weeks; the markers of the natural killer cells obtained after the multiplication culture are CD3?\CD56+, CD16+, CD57+, and CD8+, wherein CD16+/CD56+?15%, CD3?/CD56+?50%, and CD8+/CD57+?8%; then preparing an injection with a certain concentration using the cell suspension obtained by above-mentioned method.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 13, 2018
    Inventors: Qinyi Wang, Huailin Wang
  • Patent number: 10113003
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: October 30, 2018
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • Patent number: 10092634
    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: October 9, 2018
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 10064913
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: September 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Jens Fritsche, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10066207
    Abstract: The invention relates to a specialized subpopulation of natural killer cells that have enhanced effector functions and the potential to kill malignant tumor cells or infected cells when the natural killer cells are exposed to an antibody bound to the tumor cells or the infected cells.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: September 4, 2018
    Assignee: Board of Trustees of Michigan State University
    Inventors: Sungjin Kim, Jeannine Scott
  • Patent number: 10030065
    Abstract: The present invention relates to a soluble negative control MHC multimer comprising a nonsense peptide that binds the MHC protein efficiently, but that does not support binding of the resultant MHC-peptide complex to the desired T Cell Receptor. The nonsense peptide is designed to i) have a length enabling binding to the MHC allele in question, ii) have appropriate amino acids at relevant anchor positions which anchor the nonsense peptide to the peptide-binding groove of the MHC, iii) have amino acids outside the anchor positions that do not support binding to a T Cell Receptor, and iv) have an amino acid sequence that is different from the linear sequence of any naturally occurring peptide.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: July 24, 2018
    Assignee: Dako Denmark A/S
    Inventors: Liselotte Brix, Henrik Pedersen, Tina Jakobsen, Jørgen Schøller, Jesper Lohse, Katja Brunstedt, Kivin Jacobsen